Peter Rossing

Peter Rossing

Clinical Professor

Member of:

  • Internal Medicine: Endocrinology

ORCID: 0000-0002-1531-4294

Publication year:
All
31 - 40 out of 68Page size: 10
  1. 2022
  2. Published

    Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria

    McGill, J. B., Haller, H., Roy-Chaudhury, P., Cherrington, A., Wada, T., Wanner, C., Ji, L. & Rossing, Peter, 2022, In: BMJ open diabetes research & care. 10, 4

    Research output: Contribution to journal › Review › Research › peer-review

  3. Published

    16-LB: Effects of Finerenone in Patients with CKD and T2D Are Independent of HbA1c at Baseline, HbA1c Variability, and Duration of Diabetes

    Mcgill, J. B., Agarwal, R., Anker, S., Bakris, G., Filippatos, G., Pitt, B., Ruilope, L. M., Birkenfeld, A. L., Caramori, L., Brinker, M. D., Joseph, A., Lage, A. Z., Lawatscheck, R., Scott, C. & Rossing, Peter, 2022, In: Diabetes. 71, Supplement_1, 16-LB.

    Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

  4. Published

    Distal symmetrical polyneuropathy is present in all individuals with diabetes and foot ulcers - and does not associate with healing time

    Mizrak, H. I., Hansen, T. W., Andersen, Jonas Askø, Rossing, Peter, Rasmussen, A. & Hansen, C. S., 2022, In: Journal of Diabetes and its Complications. 36, 12, 108353.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis

    Pitt, B., Agarwal, R., Anker, S. D., Ruilope, L. M., Rossing, Peter, Ahlers, C., Brinker, M., Joseph, A., Lambelet, M., Lawatscheck, R. & Filippatos, G. S., 2022, In: JAMA network open. 5, 10, 10 p., E2236123.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists

    Provenzano, M., Jongs, N., Vart, P., Stefánsson, B. V., Chertow, G. M., Langkilde, A. M., McMurray, J. J. V., Correa-Rotter, R., Rossing, Peter, Sjöström, C. D., Toto, R. D., Wheeler, D. C., Heerspink, H. J. L. & DAPA-CKD Trial Committees and Investigators, D. T. C. A. I., 2022, In: Kidney International Reports. 7, 3, p. 436-443

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus

    Puig-Jové, C., Julve, J., Castelblanco, E., Julián, M. T., Amigó, N., Andersen, H. U., Ahluwalia, Tarun Veer Singh, Rossing, Peter, Mauricio, D., Jensen, M. T. & Alonso, N., 2022, In: Cardiovascular Diabetology. 21, 257.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes

    Rossing, Peter, 2022, In: Kidney International Supplements. 12, 1, p. 27-35 9 p.

    Research output: Contribution to journal › Review › Research › peer-review

  9. Published

    Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

    Rossing, P., Inzucchi, S. E., Vart, P., Jongs, N., Docherty, K. F., Jhund, P. S., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Solomon, S. D., DeMets, D. L., Bengtsson, O., Lindberg, M., Langkilde, A. M., Sjöstrand, M., Stefansson, B. V., Karlsson, C., Chertow, G. M. & 7 others, Hou, F. F., Correa-Rotter, R., Toto, R. D., Wheeler, D. C., McMurray, J. J. V., Heerspink, H. J. L. & DAPA-CKD and DAPA-HF Trial Committees and Investigators, D. A. D. T. C. A. I., 2022, In: The Lancet Diabetes and Endocrinology. 10, 1, p. 24-34 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial

    Rossing, Peter, Agarwal, R., Anker, S. D., Filippatos, G., Pitt, B., Ruilope, L. M., Amod, A., Marre, M., Joseph, A., Lage, A., Scott, C., Bakris, G. L. & the FIDELIO-DKD Investigators, T. F. I., 2022, In: Diabetes, Obesity and Metabolism. 24, 1, p. 125-134 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence

    Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., Sadusky, T., Tandon, N., Tuttle, K. R., Wanner, C., Wilkens, K. G., Zoungas, S., Craig, J. C., Tunnicliffe, D. J., Tonelli, M. A., Cheung, M. & 2 others, Earley, A. & de Boer, I. H., 2022, In: Kidney International. 102, 5, p. 990-999 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 3 4 5 6 7 Next

ID: 12937790